role of renin blockers in the prevention of diabetes

ABSTRACT

To evaluate the role of renin blockers angiotensin converting enzymes inhibitors [ACEI] or angiotensin receptor blockers [ARB] in the prevention of diabetes. We did a meta-analysis using the Cochrane group methodology of all available randomized controlled trials [RCTs] that evaluated the role of renin blockers in which outcomes of new-onset diabetes was reported. This meta-analysis was conducted between April 2005-April 2006 at King Faisal Specialist Hospital and Research Center, Riyadh, Kingdom of Saudi Arabia. Thirteen trials including 91,388 individuals met the inclusion criteria. There was a statistically significant reduction in the incidence of new-onset diabetes in patients receiving renin blockers compared to other antihypertensive agents [relative risks=0.79; 95% confidence interval=0.75-0.84]. There was a statistically significant reduction in the incidence of new-onset diabetes in patients receiving renin-blockers compared to diuretics, conventional antihypertensive therapy [diuretics or beta-blockers], and calcium channel blockers. Renin blockers reduce the incidence of new-onset diabetes and should be considered as first line therapy, when indicated, in patients at high risk for diabetes